Montelukast Junior Denk (Montelukast)

Montelukast blocks the cysteinyl leukotriene receptor CysLT1, preventing leukotriene D4 and related molecules from triggering inflammation, bronchoconstriction, and mucus production in the airways, which helps control asthma and allergy symptoms.

The appropriate dose is determined by the prescribing clinician based on the patient’s age, weight, and clinical condition. Dosage instructions are provided on the prescription label and should be followed exactly.

Safety data for montelukast in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting beta‑agonists. It is particularly useful for patients who need additional control of exercise‑induced symptoms or who prefer a non‑inhaled option, but it does not replace rescue bronchodilators.

Store the tablets at temperatures below 25 °C, in the original packaging, and protect them from moisture and direct sunlight to maintain potency throughout the shelf life.

The medication is taken orally, usually once daily in the evening, with or without food, as directed by the prescribing physician. Swallow the tablet whole; do not crush or chew unless specifically instructed.

Serious adverse reactions, though rare, include angioedema, severe skin reactions such as Stevens‑Johnson syndrome, and anaphylaxis. Patients should seek immediate medical attention if they experience swelling of the face or throat, rash, or difficulty breathing.

Montelukast should be avoided in individuals with known hypersensitivity to the drug or any of its excipients. It is also contraindicated in patients who have experienced severe allergic reactions to leukotriene receptor antagonists.